Navigation Links
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Date:4/24/2012

es the need for more effective treatments in metastatic RCC."

The FDA's Fast Track program is designed to facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening diseases with the potential to address unmet medical needs. Fast Track designation allows for the review timeline to be truncated to six months compared to the traditional 12 months.

The Phase 3 ADAPT study is a randomized, multicenter, open-label study of AGS-003 in combination with sunitinib compared to sunitinib plus placebo. Argos plans to enroll approximately 450 mRCC patients at approximately 100 clinical sites in North America and Europe. The primary endpoint for the ADAPT study is overall survival. Additional endpoints include overall response, immune response, progression-free survival and safety.

Regarding the Phase 2 clinical study, 21 patients with newly diagnosed metastatic clear cell RCC were enrolled. Treatment consisted of six-week cycles of sunitinib, four weeks on and two weeks off, plus AGS-003, which was administered as an intradermal injection every three weeks for five doses, and then every 12 weeks until progression in combination with sunitinib. Results presented during the 2012 ASCO Genitourinary Cancers Symposium indicated that the median progression-free survival in patients with newly diagnosed, unfavorable risk mRCC was 11.2 months and estimated Kaplan-Meier median overall survival was 29.3 months in this study, based upon follow-up through January 2012. In addition, AGS-003 was well tolerated in combination with sunitinib, with no immunotherapy related serious adverse events observed.   

About the Arcelis™ Technology

Arcelis is Argos's proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune respon
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
2. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
6. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
7. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... signal a positive sign for the economy , PLYMOUTH ... ( www.ecri.org ), an independent nonprofit that ... offers procurement support to more than 2,000 U.S. hospitals, ... for medical technology acquisition support, a strong signal that ...
... MONMOUTH JUNCTION, N.J., Oct. 19 Transave Inc., today ... investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic ... latest results along with previously reported data demonstrate significant ... in two indications - for the treatment of lung ...
Cached Medicine Technology:ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5
(Date:4/24/2014)... negative and stressful outcomes for parents who have a ... illness, says a recent study led by a researcher ... are numerous and life-changing and stress levels high, the ... research reported positive outcomes as well, a phenomenon known ... recent issue of the American Journal of Orthopsychiatry ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... CHAMPAIGN, Ill. It is better to give than to ... enjoy giving, a new study suggests. , The study found ... such as giving their money to family members, are less ... thrill from taking risks or keeping the money for themselves. ... of the National Academy of Sciences . , The study ...
(Date:4/24/2014)... virus caused the first flu pandemic in the 21st ... killed more than 50 people in the country. Since ... epidemics (winter/spring seasons). , Infections with influenza pH1N1 ... Health Organization has recommended Tamiflu for treatment of patients ... drug is that it targets viral proteins which mutate ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... , ... Juniper Research’s Mobile Health Opportunities Report, public and private healthcare providers will be able ... of remote patient monitoring using cellular networks by the year 2014. , ... Hampshire, UK (PRWEB) May ...
... Capture ... and tackle complex medical billing issues. , ... Washington, DC (Vocus) May 11, 2010 -- Capture Billing and Consulting, Inc. ... medical practices come together, ask questions and help each other. Over the past decade ...
... Edgy ... ... Is the primitive fear of being caught naked causing countless women to quit breastfeeding each ... to the public conversation about breastfeeding in an edgy new internet campaign that is taking ...
... ... to Dentists , ... Dallas, TX (PRWEB) May 10, 2010 -- Bold Ventures, a diversified holding company ... launched a new services company for the dental industry. The company, Dental Wealth Partners, will ...
... comes from microscopic contaminants from fuel combustion, report says ... proof that air pollution is associated with heart attack, ... Association (AHA) scientific statement released Monday. , Of the ... for fine particulate matter (called PM2.5 by scientists because ...
... study shows , MONDAY, May 10 (HealthDay News) -- Siblings ... are also more likely to suffer from the condition, a ... is published in the May issue of Archives of ... condition for both physicians and patients. , "These authors found ...
Cached Medicine News:Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 2Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 3Health News:Capture Medical Billing Launches Facebook Fan Page to Help Improve Medical Billing Issues 2Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 2Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 3Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 4Health News:Bold Ventures Launches New Healthcare Business 2Health News:Bold Ventures Launches New Healthcare Business 3Health News:Bold Ventures Launches New Healthcare Business 4Health News:Air Pollution Raises Risk of Heart Disease, Death 2Health News:Restless Legs Syndrome Can Have Family Ties 2
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: